cincorlogo.jpg
CinCor Pharma Appoints June Lee to Its Board of Directors
January 13, 2022 08:00 ET | CinCor Pharma Inc
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee...
cincorlogo.jpg
CinCor Pharma Announces Pricing of Initial Public Offering
January 06, 2022 23:26 ET | CinCor Pharma Inc
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for...
cincorlogo.jpg
CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock
January 03, 2022 07:30 ET | CinCor Pharma Inc
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of...
cincorlogo.jpg
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
December 09, 2021 08:00 ET | CinCor Pharma, Inc.
CINCINNATI, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective,...
cincorlogo.jpg
CinCor Pharma Appoints Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business Development Officer
October 28, 2021 08:00 ET | CinCor Pharma, Inc.
CINCINNATI, Oct. 28, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business...
cincorlogo.jpg
CinCor Pharma Appoints Mason Freeman, M.D., as Executive VP, Clinical Development
October 19, 2021 08:00 ET | CinCor Pharma, Inc.
CINCINNATI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Mason W. Freeman, M.D., as Executive Vice President, Clinical Development responsible...
cincorlogo.jpg
CinCor Pharma Raises $143 Million in Series B Financing
October 12, 2021 08:00 ET | CinCor Pharma, Inc.
Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary...
cincorlogo.jpg
CinCor Pharma Appoints Marc de Garidel as Chief Executive Officer
July 06, 2021 08:00 ET | CinCor Pharma, Inc.
CINCINNATI, July 06, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Marc de Garidel, currently on the Company’s Board of Directors, as Chief Executive...
cincorlogo.jpg
CinCor Pharma Announces Appointments of Three Experienced Independent Members to Its Board of Directors
May 20, 2021 08:00 ET | CinCor Pharma, Inc.
Experienced biopharmaceutical executive, John F. Thero, Chief Executive Officer of Amarin Corporation PLC, a commercial-stage cardiovascular companySeasoned biopharmaceutical finance executive, Troy...
cincorlogo.jpg
CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects
October 20, 2020 08:00 ET | CinCor Pharma, Inc.
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...